文献速递白血病造血干细胞移植与细胞治疗

CHALL-01方案对比Hyper-CVAD/MA方案治疗成人Ph阳性急性淋巴细胞白血病

[Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

该回顾性研究纳入158例≤60岁Ph阳性急性淋巴细胞白血病患者,比较Hyper-CVAD/MA方案与CHALL-01方案的疗效。两组完全缓解率无差异,但CHALL-01组分子学缓解率更高、肺部感染发生率更低,4年总生存率和无病生存率均更优。

要点

  • CHALL-01组与Hyper-CVAD/MA组完全缓解率无显著差异(91.6% vs 90.5%,P=0.811)。
  • CHALL-01组分子学缓解率显著更高(P=0.027),肺部感染发生率更低(43.4% vs 67.9%,P=0.005)。
  • CHALL-01组4年总生存率55.63%和4年无病生存率49.06%均优于Hyper-CVAD/MA组。

核心结论

  • CHALL-01方案治疗成人Ph阳性急性淋巴细胞白血病疗效优于Hyper-CVAD/MA方案,表现为分子学缓解率高、肺部感染发生率低、总生存和无病生存更优。

研究设计与样本

  • 回顾性分析2007年1月至2017年12月第二军医大学附属长海医院及长征医院收治的158例≤60岁Ph阳性急性淋巴细胞白血病患者,排除慢性髓性白血病急变期患者。
  • Hyper-CVAD/MA组63例,CHALL-01组95例;诱导及巩固化疗期间联合酪氨酸激酶抑制剂治疗,有合适供者行造血干细胞移植并用酪氨酸激酶抑制剂维持治疗。

主要发现

  • 1~2个疗程诱导后91.1%(144/158)患者获完全缓解,Hyper-CVAD/MA组90.5%(57/63),CHALL-01组91.6%(87/95),两组差异无统计学意义(χ²=0.057,P=0.811)。
  • 134例完全缓解患者可进一步分析,CHALL-01组完全分子学反应率44.4%对22.6%,主要分子学反应率9.9%对18.9%(χ²=7.216,P=0.027)。
  • Hyper-CVAD/MA组4年总生存率44.81%(95%CI 30.80%~57.86%),CHALL-01组55.63%(95%CI 39.07%~69.36%)(P=0.037)。
  • Hyper-CVAD/MA组4年无病生存率37.95%(95%CI 24.87%~50.93%),CHALL-01组49.06%(95%CI 34.24%~62.29%)(P=0.015)。
  • 两组4年累积复发率(P=0.328)及无复发死亡率(P=0.138)差异无统计学意义;CHALL-01组肺部感染发生率43.4%对67.9%(χ²=7.908,P=0.005)。

关键数值与推荐

  • 完全缓解率:Hyper-CVAD/MA组90.5%(57/63),CHALL-01组91.6%(87/95),P=0.811。
  • 完全分子学反应率:CHALL-01组44.4%对Hyper-CVAD/MA组22.6%;主要分子学反应率:CHALL-01组9.9%对Hyper-CVAD/MA组18.9%,P=0.027。
  • 4年总生存率:Hyper-CVAD/MA组44.81%(95%CI 30.80%~57.86%),CHALL-01组55.63%(95%CI 39.07%~69.36%),P=0.037。
  • 4年无病生存率:Hyper-CVAD/MA组37.95%(95%CI 24.87%~50.93%),CHALL-01组49.06%(95%CI 34.24%~62.29%),P=0.015。
  • 肺部感染发生率:CHALL-01组43.4%对Hyper-CVAD/MA组67.9%,P=0.005。

临床怎么用

  • 对于≤60岁成人Ph阳性急性淋巴细胞白血病,CHALL-01方案可作为优于Hyper-CVAD/MA方案的化疗选择,尤其关注分子学缓解和感染风险。
  • 治疗中应联合酪氨酸激酶抑制剂,有合适供者行造血干细胞移植并用酪氨酸激酶抑制剂维持。

局限性

  • 本研究为单中心及合作中心的回顾性分析,样本量有限,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the difference of efficacy between traditional Hyper-CVAD/MA regimen and the adolescents inspired chemotherapy regimen, CH ALL-01, in treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) . Methods: In this study we retrospectively analyzed 158 Ph(+) ALL patients receiving Hyper-CVAD/MA regimen (n=63) or CHALL-01 regimen (n=95) in our center and Changzheng hospital from January 2007 to December 2017, excluding patients with chronic myeloid leukemia in blast crisis. Tyrosine kinase inhibitor (TKI) was administered during induction and consolidation chemotherapy. Patients who underwent hematopoietic stem cell transplantation received TKI as maintenance therapy. Results: Of them, 91.1% (144/158) patients achieved complete remission (CR) after 1-2 courses of induction. CR rate was 90.5% (57/63) for patients in Hyper-CVAD/MA group and 91.6% (87/95) for patients in CHALL-01 group. There was no difference in CR rates between the two groups (χ(2)=0.057, P=0.811) . The last follow-up was June 2018. A cohort of 134 CR patients could be used for further analysis, among them, 53 patients received Hyper-CVAD/MA regimen and other 81 patients received CHALL-01 regimen. The molecular remission rates were significantly higher in CHALL-01 group (complete molecular response: 44.4%vs 22.6%; major molecular response: 9.9% vs 18.9%) (χ(2)=7.216, P=0.027) . For the patients in Hyper-CVAD/MA group, the 4-year overall survival (OS) was 44.81% (95%CI: 30.80%-57.86%) and the 4-year disease free survival (DFS) was 37.95% (95%CI: 24.87%-50.93%) . For patients received CHALL-01 regimen, the 4-year OS was 55.63% (95%CI: 39.07%-69.36%) (P=0.037) and 4 year DFS was 49.06% (95%CI: 34.24%-62.29%) (P=0.015) , while there was no significant difference in 4 year cumulative incidence of relapse (CIR) (P=0.328) or cumulative incidence of nonrelapse mortality (CI-NRM) (P=0.138) . The rate of pulmonary infection was lower in patients received CHALL-01 regimen compared with patients received Hyper-CVAD regimen (43.4% vs 67.9%, χ(2)=7.908, P=0.005) . Conclusions: Outcome with CHALL-01 regimen appeared better than that with the Hyper-CVAD/MA regimen in Ph(+) ALL, which has lower incidence of pulmonary infection, higher molecular remission rate and better OS and DFS. 目的: 比较传统Hyper-CVAD/MA方案及借鉴儿童急性淋巴细胞白血病(ALL)的新化疗方案CHALL-01在≤60岁成人Ph阳性ALL(Ph(+) ALL)中的临床疗效。 方法: 回顾性分析2007年1月至2017年12月第二军医大学附属长海医院及长征医院收治的158例Ph(+) ALL患者(除外慢性髓性白血病急变期患者),其中Hyper-CVAD/MA组63例,CHALL-01组95例,诱导及巩固化疗期间联合酪氨酸激酶抑制剂(TKI)治疗,有合适供者的患者进行造血干细胞移植,并用TKI进行维持治疗。 结果: 经过1~2个疗程的诱导治疗,91.1%(144/158)患者获得完全缓解(CR),其中Hyper-CVAD/MA组CR率为90.5%(57/63),CHALL-01组CR率为91.6%(87/95),两组间差异无统计学意义(χ(2)=0.057,P=0.811)。随访截止于2018年6月,共134例CR患者可进一步分析,其中Hyper-CVAD/MA组53例,CHALL-01组81例。CHALL-01组达到分子学缓解的比例显著高于Hyper-CVAD/MA组(完全分子学反应率:44.4%对22.6%,主要分子学反应率:9.9%对18.9%)(χ(2)=7.216,P=0.027)。Hyper-CVAD/MA组和CHALL-01组4年总生存率分别为44.81%(95%CI 30.80%~57.86%)和55.63% (95%CI 39.07%~69.36%)(P=0.037),4年无病生存率分别为37.95%(95%CI 24.87%~50.93%)和49.06%(95%CI 34.24%~62.29%)(P=0.015)。两组在4年累积复发率(P=0.328)及无复发死亡率(P=0.138)上差异无统计学意义。CHALL-01组肺部感染发生率较Hyper-CVAD/MA组明显减低(43.4%对67.9%,χ(2)=7.908,P=0.005)。 结论: CHALL-01方案治疗成人Ph(+) ALL疗效优于Hyper-CVAD/MA方案,肺部感染发生率低,分子学缓解率高,可以提高Ph(+) ALL患者的生存率。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Huang AJ, Wang LB, Du J, et al. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495127. doi:10.3760/cma.j.issn.0253-2727.2019.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。